ABL Diagnostics Targets Drug-Resistant Tuberculosis with Advanced Diagnostic Tools
Paris, Friday, 20 March 2026.
On March 20, 2026, ABL Diagnostics expanded its portfolio to target drug-resistant tuberculosis, introducing advanced sequencing solutions that unlock new revenue streams in the infectious disease market.
Expanding the Diagnostic Arsenal for Tuberculosis
The Woippy-based company is integrating its existing CE-IVD marked DeepChek Assay 13-Plex KB—a multiplex polymerase chain reaction (PCR) solution used to detect resistance mutations against first- and second-line treatments—with its BacterioChek software and novel next-generation sequencing (NGS) tools [1]. Specifically, the firm has developed a 19-gene resistance panel and a comprehensive whole genome Mycobacterium tuberculosis (MTB) solution spanning approximately 4.4 megabases (Mb), utilizing capture technology primarily for research applications [1].
Strengthening Corporate Structure and Market Visibility
This scientific advancement follows closely on the heels of strategic corporate maneuvering. On March 17, 2026, ABL Diagnostics disclosed that its primary shareholder, the Luxembourg-based Advanced Biological Laboratories (ABL), executed the sale of a new block of shares [2][3]. The transaction was conducted over-the-counter with a private third party, and the requisite filings were submitted to the French Financial Markets Authority (AMF) [2][3]. This financial operation is part of a broader initiative supported by the main shareholder to enhance the company’s visibility among investors, partners, and the broader healthcare market [2].
Strategic Partnerships and Global Logistics Expansion
The synergistic relationship with CDL Pharma has already yielded tangible commercial results. On February 18, 2026, the two entities announced the multi-year renewal of a clinical services agreement with the French pharmaceutical company Servier [4]. This partnership validates the group’s integrated model, which provides sponsors with an end-to-end pathway ranging from clinical sample management to advanced molecular analysis [4]. Chalom Sayada, President and CEO of ABL Diagnostics and CDL Pharma, noted that the continued collaboration ensures simplified execution, tailored project management, and consistent molecular outputs for their long-standing pharmaceutical partners [4].